SAN DIEGO, April 18, 2017 /PRNewswire/ -- Biocept, Inc.
(NASDAQ: BIOC), a leading commercial provider of liquid biopsy
tests designed to provide physicians with clinically actionable
information to improve the outcomes of cancer patients, announces
that it has been awarded Japanese Patent No. 6081434 entitled,
DEVICES AND METHODS OF CELL CAPTURE AND ANALYSIS. The issued patent
covers the use of antibodies for the capture of any target of
interest from any sample type on a device surface. This includes
CTCs, as well as other targets of interest such as sub-cellular
vesicles and exosomes that are shed by solid tumors into the blood
stream. This patent is broader than previously issued patents owned
by the Company, and is the nineteenth patent issued to Biocept
related to its core liquid biopsy technology.
"The granting of this patent significantly expands the
intellectual property protecting Biocept's CTC technology
platform," said Lyle Arnold, Ph.D.,
Chief Scientific Officer at Biocept. "Our unique CTC and ctDNA dual
platform approach allows us to provide an expanded set of biomarker
content to aid physicians in making optimal treatment decisions for
their cancer patients."
Michael Nall, Biocept's President
and CEO, added, "This is our third patent issued in Japan, strengthening the protection of our
proprietary liquid biopsy technology in an important healthcare
market. Expanding our intellectual property is consistent with our
strategy to leverage our patent estate by licensing our technology
for global distribution and commercialization."
About Biocept
Biocept, Inc. is a molecular diagnostics company with
commercialized assays for lung, breast, gastric, colorectal and
prostate cancers, and melanoma. The Company uses its proprietary
liquid biopsy technology to provide physicians with clinically
actionable information for treating and monitoring patients
diagnosed with cancer. The Company's patented Target Selector™
liquid biopsy technology platform captures and analyzes
tumor-associated molecular markers in both circulating tumor cells
(CTCs) and in circulating tumor DNA (ctDNA). With thousands of
tests performed, the platform has demonstrated the ability to
identify cancer mutations and alterations to inform physicians
about a patient's disease and therapeutic options. For additional
information, please visit www.biocept.com.
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based
upon current expectations or beliefs, as well as a number of
assumptions about future events. Although we believe that the
expectations reflected in the forward-looking statements and the
assumptions upon which they are based are reasonable, we can give
no assurance that such expectations and assumptions will prove to
have been correct. Forward-looking statements are generally
identifiable by the use of words like "may," "will," "should,"
"could," "expect," "anticipate," "estimate," "believe," "intend,"
or "project" or the negative of these words or other variations on
these words or comparable terminology. To the extent that
statements in this release are not strictly historical, including
without limitation statements as to our ability to improve the
outcomes of cancer patients, and our ability to leverage our patent
estate by licensing our technology for global distribution and
commercialization, such statements are forward-looking, and are
made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. The reader is cautioned
not to put undue reliance on these forward-looking statements, as
these statements are subject to numerous risk factors as set forth
in our Securities and Exchange Commission (SEC) filings. The
effects of such risks and uncertainties could cause actual results
to differ materially from the forward-looking statements contained
in this release. We do not plan to update any such forward-looking
statements and expressly disclaim any duty to update the
information contained in this press release except as required by
law. Readers are advised to review our filings with the SEC, which
can be accessed over the Internet at the SEC's website located at
www.sec.gov.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/biocept-awarded-additional-patent-in-japan-expanding-intellectual-property-estate-to-19-issued-patents-protecting-its-target-selector-liquid-biopsy-platform-300440344.html
SOURCE Biocept, Inc.